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Abstract
Human immunodeficiency virus (HIV)-associated adipose redistribution syndrome (HARS) is a fat
accumulation disorder characterized by increases in visceral adipose tissue. Patients with HARS
may also present with excess truncal fat and accumulation of dorsocervical fat ("buffalo hump").
The pathophysiology of HARS appears multifactorial and is not fully understood at present. Key
pathophysiological influences include adipocyte dysfunction and an excessive free fatty acid release
by adipocyte lipolysis. The contributory roles of free fatty acids, cytokines, hormones including
cortisol, insulin and the growth hormone-adipocyte axis are significant. Other potential humoral,
paracrine, endocrine, and neural influences are also discussed.
Background
Active antiretroviral therapy has reduced mortality of
AIDS (acquired immune deficiency syndrome) and
increased both the quality of life and longevity in patients
infected with HIV (human immunodeficiency virus).
However, long-term effects of HIV infection are increas-
ingly observed [1,2]. Among the more apparent effects are
changes in fat distribution or "lipodystrophy," which
includes fat loss or "lipoatrophy" and/or an increase in fat
accumulation, also known as "lipohypertrophy" [3]. The
pathological aberrations of fat metabolism seen in some
HIV-infected patients remain inadequately understood
and controversial despite extensive studies[4]. These
changes may be an outcome of HIV itself or that of active
antiretroviral therapy. Lipoatrophy and lipohypertrophy
may occur separately or together in an individual.
The term HIV-associated adipose redistribution syndrome
(HARS) describes a fat accumulation disorder in patients
with HIV, which has specific characteristics. The primary
characteristic is an increase in the amount of visceral adi-
pose tissue (VAT) [5], often observed in patients while
they are undergoing active anti-retroviral therapy[6]. In
addition, adipose tissue may accumulate subcutaneously
in regions such as the trunk and the dorsocervical area –
where a significant depot may be referred to as a "buffalo
hump". Further, metabolic perturbations including insu-
lin resistance, glucose intolerance, dyslipidemia and
hypertension, as well as body image distress may accom-
pany these changes. These metabolic disturbances may
portend the development of other, more serious, medical
conditions including diabetes mellitus and cardiovascular
disease [7-9]. While the most commonly observed form of
HIV lipodystrophy is lipoatrophy[10], patients with
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taneous adipose tissue (SAT), including abdominal
SAT[11]. In this review, we address potential pathophysi-
ologic mechanisms to explain HARS and its associated
health risks.
Etiology and Pathogenesis of HARS
Although the underlying mechanisms of HIV-associated
lipodystrophy and HARS remain unclear, investigators
show increasing interest in teasing apart the various
aspects of HIV-lipodystrophy. While peripheral fat loss
and central fat accumulation may be seen in the same
patient, there is no statistically significant relationship
between the two conditions[12], so a single metabolic
process is unlikely to simultaneously decrease and
increase fat in the same patient. Though the term "redistri-
bution" is used in HARS and the Fat Redistribution and
Metabolic Changes in HIV Infection Study (FRAM), it is
not meant to imply the migration of fat from one depot to
another. Rather, it refers to the overall re- or maldistribu-
tion of fat as adipose tissue atrophies in some areas, e.g.,
face, buttocks and limbs, and at the same time fat accumu-
lates or hypertrophies in other areas, e.g. in the abdomen
as VAT.
The etiology of HIV lipodystrophy, and HARS in particu-
lar, is certainly multifactorial. Intrinsic host factors, dis-
ease status, treatment duration and type, as well as other
factors probably all play a role. Evidence summarized by
Lichtenstein[13] suggests that significant risk factors for
fat loss include exposure to and duration of thymidine
analogues (particularly the older ones, stavudine, zidovu-
dine), age, CD4-positive count, viral load, duration of
therapy, and white race. In contrast, risk factors for abnor-
mal fat accumulation include duration of therapy, CD4-
positive count, viral load, age, protease inhibitor use (par-
ticularly the older ones, indinavir, nelfinavir), and female
sex[14]. These differences in risk factors for the two man-
ifestations of lipodystrophy suggest that the pathogenic
mechanisms for fat redistribution, loss versus gain, are
probably independent and the result of complex interac-
tions of host, disease and drug factors.
Pathogenic Influences
Visceral and subcutaneous fat depots are genetically and
metabolically different from each other. Surgical removal
of VAT in animals and humans improved insulin resist-
ance and glucose while removal of SAT did not [15-17].
Acute increases in glucose uptake into adipose tissue by
either hyperglycemia or hyperinsulinemia increased the
expression of several fat-derived peptides to a greater
extent in VAT than in SAT[18].
It is known that the metabolic function of adipose tissue
is controlled by numerous humoral, paracrine, and intra-
crine factors[19], as well as by sympathetic innervation
(stimulating lipolysis) and parasympathetic innervation
(parasympathectectomy can induce insulin resistance in
the denervated fat depot) [20,21]. It is likely that disrup-
tion of these complex interacting regulatory pathways, in
various ways (e.g. by HIV itself or its treatment), accounts
for at least some of the fat maldistribution and metabolic
consequences seen in HARS. Chronic disruption of para-
crine interactions between lymphoid and adipose tissue
may play a role in HARS[19], while HIV or antiretroviral
agents may adversely affect neural pathways to different
fat depots[20].
Adipocyte Dysfunction
Among the observed endocrine and cytokine alterations
in HIV lipodystrophy are increased levels of insulin[22]
and tumor necrosis factor-α (TNF-α)[19] and defects in
the secretion of growth hormone (GH), all of which may
alter adipocyte function. The problem in understanding
the pathogenesis of HARS, however, is that the observed
metabolic effects associated with HIV lipodystrophy are
the sum of multiple metabolic disturbances, each a sepa-
rate component.
Disruption of specific regulatory controls of VAT may
account for HARS. VAT may differ from SAT tissue in func-
tion, however, recent data from FRAM suggests that both
VAT and upper trunk SAT are independently associated
with insulin resistance[23]. A critical VAT threshold may
exist, whereby signs of metabolic syndrome do not appear
until the VAT mass exceeds this level for a given individ-
ual[24].
Leptin
Leptin is an adipocyte-derived hormone and its plasma
levels directly correlate with adipose tissue mass (SAT
rather than VAT). Leptin is involved in the regulation of
energy homeostasis and has peripheral effects on fatty
acid oxidation. Fasting leptin levels have been shown to
correlate with total body fat concentrations in HIV-
infected patients[25]. Nagy et al. found that leptin levels
were lowest in HIV patients exhibiting lipoatrophy, inter-
mediate in those with mixed lipodystrophy or normal
body habitus, and highest in those with lipohypertro-
phy[26]. These findings could be attributed to a reduction
in leptin synthesis in those with lipoatrophy and reduced
SAT[27] and excess circulating levels of leptin due to lep-
tin resistance in those with VAT hypertrophy[25]. This
leptin resistant state might also be associated with meta-
bolic syndrome and insulin resistance in HIV patients
with lipohypertrophy[25].
Adiponectin
Adiponectin improves insulin sensitivity, and reduced
adiponectin is associated with insulin resistance, hyper-Page 2 of 7
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treated with HAART[28]. An inverse relation has been
found between adiponectin levels and VAT mass, serum
triglycerides and insulin resistance in HIV patients. These
findings are consistent with the role of VAT in the devel-
opment of insulin resistance and lipid abnormalities asso-
ciated with the metabolic syndrome. Since adiponectin
expression is higher in SAT than VAT, accumulation of
VAT combined with SAT loss may lead to decreased adi-
ponectin production in both lipoatrophy and HARS[25].
Hadigan et al. demonstrated depot-specific regulation of
glucose uptake and insulin sensitivity in fat and muscle,
with a possible role of adiponectin associated with area of
VAT and total body disposal of glucose[29]. Although glu-
cose uptake by SAT was greater in HIV-infected than non-
infected men, there was no difference in glucose uptake by
VAT. VAT area was strongly correlated (r2 = 0.94, P <
0.0001) with whole-body glucose disposal, perhaps medi-
ated by adiponectin. Lundgren et al. have demonstrated
that VAT of non-HIV patients normally has a two-fold
higher glucose uptake rate compared with SAT[30].
Plasminogen Activator Inhibitor Type-1
Proinflammatory cytokine activity may be increased in
HIV-infected patients with lipodystrophy[31]. Plasmino-
gen activator inhibitor type-1 (PAI-1) is a multifaceted
proteolytic factor. It plays an important role in signal
transduction, cell adherence and cell migration; and is
found in plasma and adipose tissue, is increased in obes-
ity, and predicts cardiovascular disease. PAI-1 is associated
with proinflammatory adipokines, such as TNF-α and
interleukin-6 (IL-6). It has also been reported to be ele-
vated in HIV-associated lipodystrophy syndrome, along
with a three-fold elevation of visceral fat, and reduced
peripheral fat[32].
Uncoupling Proteins
The central role of uncoupling proteins in the several
pathways that control VAT function may explain the mul-
tifactorial nature of HARS metabolic complications[33].
Recent results establish uncoupling protein-2 as a key
component of β-cell glucose sensing, and as a critical link
between obesity, β-cell dysfunction and type 2 diabe-
tes[34].
Local Cortisol and 11-β-HSD1
Although elevated cortisol or abnormalities of the gluco-
corticoid receptor have been excluded as a potential cause
of HIV lipodystrophy, this does not rule out the possibil-
ity of a local effect of cortisol on adipose depots in HIV
lipodystrophy[35]. Cortisol is known to promote adipo-
genesis[13], thus increased local cortisol concentrations
may increase VAT. VAT cells express high levels of the
enzyme 11-beta hydroxysteroid dehydrogenase type 1
(11-β-HSD1), which helps catalyze inactive cortisone to
cortisol. Sutinen et al. showed significantly higher levels
of 11-β-HSD1 in the SAT of HIV lipodystrophy patients
compared to non-lipodystrophy cases[36]. Transgenic
mice overexpressing this enzyme develop a full-blown
metabolic syndrome with obesity and increased amounts
of VAT [37]. Insulin can stimulate 11-β-HSD1 [38], and
insulin resistance could lead to elevated insulin levels,
which might ultimately increase VAT by stimulating the
increase in local cortisol production.
Growth Hormone and 11-β-HSD1
Evidence suggests that reduced growth hormone (GH)
may play a role in the local regulation of cortisol in VAT
by 11-β-HSD1. GH inhibits 11-β-HSD1 in adipose tissue,
which may result in reduced active cortisol to stimulate
VAT production[22]. D'Amico and colleagues note
decreased lipolytic rates with a physiological replacement
dose of GH administered to HARS patients with GH defi-
ciency identified by dynamic testing[39]. They suggest
that this effect may be modulated by a reduction in adi-
pose cortisol concentrations[39].
Cytokines, Free Fatty Acids and Insulin Resistance
Long-term adaptive changes occur in adipose tissue in
chronic disease[19]. Visceral fat drains via the portal vein
into the liver and may contribute to elevated serum trig-
lycerides and insulin resistance seen in lipodystrophy
patients. It is possible that increased cytokine (TNF-α, IL-
6) secretion from adipose tissue, and increased systemic
proinflammatory cytokine activity may play a role in the
remodeling of adipose tissue and metabolic abnormali-
ties seen in patients with HIV-associated lipodystrophy
[31]. The increase in the plasma levels of free fatty acids
(FFAs), TNF-α and IL-6, along with a decrease in adi-
ponectin, together could induce liver and skeletal muscle
insulin resistance and dyslipidemia. The resulting
increased disposal of FFA would be preferentially stored
in VAT, leading to VAT lipohypertrophy [40]. Therefore,
visceral adiposity may be an initial adaptive response of
the body to prevent a rise in levels of FFAs, and an effort
to reduce potential lipotoxic damage to other organs
resulting from the increase in total triglycerides, triglycer-
ide-rich lipoproteins and raised low-density lipoprotein
levels.
Effects of Lipolysis
In the fasted state, HARS is characterized by an excessive
FFA release by adipocyte lipolysis, resulting in a greater
net delivery of FFA to the plasma, ultimately resulting in
greater hepatic delivery and export as triglyceride-rich very
low density lipoprotein (VLDL) leading to hypertriglycer-
idemia[22,41,42]. In the fed state, a different mechanism
results in a second contribution to the hypertriglyceri-
demia associated with HARS. Examination of the disposalPage 3 of 7
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in HARS patients showed a marked retardation of the
labeled fatty acids from the chylomicrons compared to
controls. Further, of the small amount cleared, a greater
proportion of the released FFA was found within the
plasma rather than taken into the adipocyte in HARS
patients suggesting that there was an adipocyte defect
resulting in impaired fat storage [43].
The mechanism underlying lipodystrophy may involve
the regulation of adipocyte hormone-sensitive lipase; the
result is an accelerated rate of whole-body lipolysis that
facilitates the "redistribution" of fat. Results of a study in
men with both peripheral fat loss and central fat accumu-
lation, as well as dyslipidemia suggested that a regulatory
defect in adipocyte lipolysis could account for both the
dyslipidemia and the peripheral fat loss [42]. Hyperlipol-
ytic activity and increased release of FFAs would promote
processes for which fatty acids are substrates, for example,
the hepatic extraction and conversion to glycerolipids.
This mechanism could explain the hypertriglyceridemia
seen in HIV-infected patients with lipodystrophy, but
does not explain the central adiposity seen in some of
them. The authors conjecture that either decreased lipoly-
sis or increased deposition of fatty acids outstripping
lipolysis in visceral fat depots might account for the
observed central adiposity [42]. This is further discussed
below.
Sekhar and colleagues have posited a basic defect in fatty
acid metabolism in peripheral adipocytes in HARS
patients to account for: the acceleration in lipolysis (pri-
marily in the femoral-gluteal region), release of fatty acids
for hepatic re-esterification leading to hypertriglyceri-
demia, along with decreased clearance of chylomicron
triglyceride[43]. The greater availability of fatty acids
increases uptake by the visceral adipocytes, which have a
higher lipid turnover rate than peripheral adipocytes,
favoring greater net deposition of fat and the develop-
ment of central adiposity. The underlying causal factor
may be the HAART agents or proteins expressed by the
virus itself. The net result is increased triglyceride deposi-
tion in the liver, central fat, and skeletal muscle; and an
increase in proatherogenic lipoproteins or "systemic stea-
tosis".
In this "systemic steatosis" model[44], increased uptake of
fatty acids in the liver promotes the synthesis of triglycer-
ides and apolipoprotein B, reduces degradation of apoli-
poprotein B, and leads to hypertriglyceridemia due to
increased production of VLDL. Lipid uptake within the
central fat depots is higher than in peripheral fat depots
(femoral-gluteal regions). High fat diets cause overexpres-
sion of the endothelial cell enzyme lipoprotein lipase,
which hydrolyzes lipids in lipoproteins. The differential
lipid uptake in the "systemic steatosis" model may there-
fore be due to an increased sensitivity to lipoprotein
lipase-activating hormones (e.g. cortisol in omental adi-
pocytes), thus sequestering fatty acids as di- and tri-glycer-
ides in abdominal visceral depots[44].
Implications of Fatty Acid Blockade
Inhibition of peripheral lipolysis improves insulin sensi-
tivity in protease inhibitor-treated men with signs of lipo-
dystrophy[45]. On the assumption that increased
circulating fatty acids contribute to hepatic insulin resist-
ance and decreased insulin signaling through insulin
receptor substrate, Hadigan and colleagues investigated
the effects of acute lipolytic blockade with the nicotinic
acid analog acipimox, which inhibits fatty acid
release[41]. Patients in this study had significant central
adiposity (body mass index 28.8 ± 1.9 kg/m2; extremity
fat 15.9 ± 2.4%; trunk fat 25.8 ± 2.2%; VAT 156.3 ± 2.8
cm2; waist-to-hip ratio [WHR] 0.99 ± 0.01). Six of the
seven subjects who received acipimox showed improve-
ment in the insulin sensitivity index; and fatty acid area
under the curve correlated inversely with insulin sensitiv-
ity (r = -0.75, P < 0.05) [41]. More recently, Hadigan et al.
reported on the 3-month use of acipimox in HIV-infected
men and women with hypertriglyceridemia. Acipimox led
to a significant sustained reduction in FFA, decreased rates
of lipolysis, and a 34 mg/dL mean reduction in triglycer-
ide concentration and improved insulin sensitivity at 3
months[46]. This supports the concept that excessive
release of fatty acids contributes to hepatic adiposity and
systemic insulin resistance[47].
A Consequence of Immune Reconstitution
HIV causes immune dysregulation and immune defi-
ciency; either or both may play a role in fat redistribution.
It could be due to the partial immune reconstitution that
occurs from successful therapy, or there may be an abnor-
mal immune response to therapy. When CD4 levels start
to return to normal after effective HIV therapy, the
immune system is not normalized; some patients still
experience an opportunistic illness[48]. It is possible that
perhaps an immune system continues to be "turned on",
to respond to HIV that is no longer detectable, and attacks
and kills subcutaneous fat cells–immune reconstitution
syndrome. The apoptotic subcutaneous adipose cells
would no longer serve as a viable storage depot for triglyc-
erides and FFAs. The atrophic SAT may also release FFAs,
which could find their way to VAT. Mitochondrial toxicity
due to antiretroviral medication or the HIV itself could
result in fat apoptosis. Many potential explanations are
being offered, but research has yet to fully elucidate this
phenomenon. Though HAART normally induces immune
reconstitution, a problem can arise when the immune
reconstitution is excessive or inappropriate.Page 4 of 7
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HARS may be considered a state of functional GH defi-
ciency. Normally, GH is released in pulsatile fashion by
the somatotrophic cells of the anterior pituitary in
response to growth hormone-releasing hormone
(GHRH), somatostatin, insulin-like growth factor (IGF-I),
thyroid hormone, and glucocorticoids. Although GHRH
is released primarily by the hypothalamus, it is also syn-
thesized in the placenta, ovary, testis, lymphocyte, pan-
creas, and gastrointestinal tract. The complexity of GH
regulation suggests the corresponding complexity of its
function in the body. GH concentrations vary inversely
with excess weight (obesity). Both reduced GH secre-
tion[49,50] and increased clearance have been associated
with visceral adiposity in non-HIV patients[51].
Rietschel and colleagues have found normal concentra-
tions of IGF-I but reduced GH concentrations in patients
with HARS, suggesting greater receptor sensitivity to GH
so that a smaller amount of GH stimulates a normal
amount of IGF-I release[52]. Patients in this study were
HIV-infected men in whom weight and total body fat were
normal but visceral fat depots were enlarged while periph-
eral fat depots were reduced. The study found 33%-38%
prevalence of deficient GH response in lipodystrophic
subjects (peak GH stimulatory cut-off values 3.0 μg/mL to
5.0 μg/mL with arginine testing). Reduced mean over-
night GH concentration (i.e., reduced basal GH concen-
tration and reduced GH pulse amplitude associated with
normal IGF-I) was observed in HAART-treated adults with
excess VAT. VAT was the most significant predictor of GH
secretion in these subjects.
The actions of the hypothalamic hormone, somatostatin,
play a role in GH regulation as well as adipose metabo-
lism. Release of somatostatin is counter regulatory in that
it inhibits GH secretion. Koutkia and colleagues com-
pared the difference in GH release by GHRH+arginine
stimulation with GHRH alone in 13 HIV-infected men
with lipodystrophy and 10 HIV-infected men without
lipodystrophy after an overnight fast[27]. VAT in the lipo-
dystrophy group was 197 ± 19 cm2 vs 66 ± 10 cm2 for the
non-lipodystrophy men, and 94 ± 13 cm2 for the compar-
ison group. The data demonstrated GH deficiency in 18%
of the lipodystrophy group vs 5.9% of the non-lipodystro-
phy group and 0% of the comparison group, using the
stringent criterion of 3.3 ng/ml for peak GH response to
GHRH-arginine. Among the lipodystrophy patients, the
peak GH response to GHRH-arginine was significantly
predicted by VAT (P = 0.008), FFA (P = 0.04) and insulin
level (P = 0.007) in regression modeling. These data dem-
onstrate increased frequency of GH deficiency in HIV
lipodystrophy patients in conjunction with increased
VAT[53]. The addition of arginine to GHRH in the lipod-
ystrophy patients led to a 247% greater increase in GH
secretion compared to the lipodystrophy patients who
received only GHRH. Since arginine blocks somatostatin's
inhibition of GH release, this suggests that patients with
HIV lipodystrophy and increased visceral fat have elevated
somatostatin tone.
Circulating FFAs may impair GH secretion; conversely,
GH replacement demonstrates marked reductions in total
and net lipolysis and the availability of FFAs for hepatic
reesterification[39]. These results highlight the complex
relationship between FFA and GH.
GH Secretion: Effects of Gender, Race and Fat Distribution
Koutkia et al. demonstrated that HIV-infected men with
fat redistribution have significantly lower GH peak
responses and higher failure rates to standardized GH
stimulation testing in comparison to healthy male control
subjects and to HIV-infected women of similar age and
body mass[27]. Furthermore, their data suggest that rela-
tive GH deficiency is very common among HIV-infected
men, especially in those with elevated WHR, even if it was
increased due to primary fat loss from the hip region.
There was a gender effect – fewer HIV-infected women
failed GHRH + arginine stimulation. Among men, a cutoff
of 7.5 ng/ml for peak GH was used to show a failure rate
of 37% vs 8% for control groups (P = 0.004). Thus, one-
third of the men with fat redistribution in this study can
be considered at least relatively GH deficient. In contrast
to patients with true GH deficiency, e.g. due to a pituitary
tumor or radiation, patients in this study were presumed
to have otherwise normal pituitary function. Among
women, no specific cutoff could be determined to sepa-
rate HIV-infected and control subjects. This may be due to
the effects of estrogen on the GH/IGF-1 axis in this rela-
tively young population and might be different for an
older or postmenopausal population.
In the same study, there were differences by race in these
patients with HIV and fat redistribution. Non-Caucasian
HIV-infected men had higher GH responses to stimula-
tion than Caucasian male HIV-infected subjects. In con-
trast, non-Caucasian HIV-infected women, compared to
Caucasian HIV-infected women, had lower GH responses.
Conclusion
The underlying pathophysiologic mechanisms responsi-
ble for HARS are multifactorial and not well understood
at present. These may include dysfunction of the GH axis,
alterations in immune function, along with increased lev-
els of insulin and various other hormones, cytokines and
proteins. Factors contributing to the dysfunction of the
GH axis may also be multifactorial. Further understanding
of these pathophysiological factors is needed for a com-
plete understanding of HIV lipodystrophy. We can expect
that future research will gradually elucidate the complexPage 5 of 7
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health-threatening, conditions associated with HARS.
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